3-Methoxyphencyclidine (3-MeO-PCP) is a dissociative pain relieving medicine that has been sold online as an organizer sedate. The compound was at first coordinated in 1979 to look into the structure-activity relationship of phencyclidine subordinates. The development of 3-meo-pcp in individuals was not depicted until 1999 when a researcher using the pen name Q. Beagle created that 3-MeO-PCP was subjectively similar to PCP with for all intents and purposes indistinguishable potency. 3-MeO-PCP binds to the NMDA receptor with higher favoritism than PCP and has the most important proclivity of the three isomeric anisyl-substitutions, trailed by 2-MeO-PCP and 4-MeO-PCP. Regardless of the way that 3-MeO-PCP is consistently delineated as having opioid or dopaminergic movement, this supposition is disavowed by data exhibiting 3-MeO-PCP to be an intense and specific ligand for the NMDA receptor without impressive proclivity for the µ-opioid receptor or dopamine transporter. 3-MeO-PCP was gone before by the less solid dissociative 4-MeO-PCP and initially wound up doubtlessly available as an examination blend.
3-MeO-PCP hydrochloride is a white crystalline solid with a dissolving reason for 204-205 °C
3-MeO-PCP has a Ki of 20 nM for the NMDA receptor, 216 nM for the serotonin transporter and 42 for the sigma1 receptor
Consultative Gathering on the Abuse of Medications in the Unified Kingdom released a report about methoxetamine, saying that the “harms of methoxetamine are equal with Class B of the Abuse of Medications Act (1971)”, regardless of the way that the show does not arrange sedates in perspective of devilishness. The report proceeded to suggest that all analogs of MXE should in like manner advance toward getting to be class B calms and prescribed a catch-all arrangement covering both existing and unresearched arylcyclohexamines, including 3-MeO-PCP